CDK9-IN-1

• Description:

  CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC50 of 39 nM for CDK9/CycT1, extracted from reference, compound 87.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  CDK; HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Cell Cycle/DNA Damage

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Infection

• Assay Protocol:

  https://www.medchemexpress.com/cdk9-in-1.html

• Concentration:

  10mM

• Purity:

  98.52

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC1=C(NS(C)(=O)=O)C=C(NC2=NC=NC(C3=CC=CC(N4C(C5=C(C=CC=C5)C4=O)=O)=C3)=C2)C=C1

• Molecular Formula:

  C26H21N5O4S

• Molecular Weight:

  499.54

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Nemeth G, et al. Novel, selective CDK9 inhibitors for the treatment of HIV infection. Curr Med Chem. 2011;18 (3) :342-358.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  CDK9; HIV-1

• CAS Number:

  [1415559-43-1]